vs

Side-by-side financial comparison of California BanCorp \ CA (BCAL) and BICYCLE THERAPEUTICS PLC (BCYC). Click either name above to swap in a different company.

BICYCLE THERAPEUTICS PLC is the larger business by last-quarter revenue ($48.0M vs $45.9M, roughly 1.0× California BanCorp \ CA). California BanCorp \ CA runs the higher net margin — 35.8% vs -42.0%, a 77.8% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs 0.8%). California BanCorp \ CA produced more free cash flow last quarter ($56.9M vs $-19.9M). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 44.7%).

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

BCAL vs BCYC — Head-to-Head

Bigger by revenue
BCYC
BCYC
1.0× larger
BCYC
$48.0M
$45.9M
BCAL
Growing faster (revenue YoY)
BCYC
BCYC
+1192.5% gap
BCYC
1193.3%
0.8%
BCAL
Higher net margin
BCAL
BCAL
77.8% more per $
BCAL
35.8%
-42.0%
BCYC
More free cash flow
BCAL
BCAL
$76.9M more FCF
BCAL
$56.9M
$-19.9M
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
44.7%
BCAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCAL
BCAL
BCYC
BCYC
Revenue
$45.9M
$48.0M
Net Profit
$16.4M
$-20.2M
Gross Margin
Operating Margin
48.8%
-51.5%
Net Margin
35.8%
-42.0%
Revenue YoY
0.8%
1193.3%
Net Profit YoY
-2.1%
61.1%
EPS (diluted)
$0.50
$-0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCAL
BCAL
BCYC
BCYC
Q4 25
$45.9M
$48.0M
Q3 25
$45.2M
$11.7M
Q2 25
$44.3M
$2.9M
Q1 25
$44.8M
$10.0M
Q4 24
$45.5M
$3.7M
Q3 24
$38.1M
$2.7M
Q2 24
$22.2M
$9.4M
Q1 24
$21.9M
$19.5M
Net Profit
BCAL
BCAL
BCYC
BCYC
Q4 25
$16.4M
$-20.2M
Q3 25
$15.7M
$-59.1M
Q2 25
$14.1M
$-79.0M
Q1 25
$16.9M
$-60.8M
Q4 24
$16.8M
Q3 24
$-16.5M
$-50.8M
Q2 24
$190.0K
$-39.8M
Q1 24
$4.9M
$-26.6M
Operating Margin
BCAL
BCAL
BCYC
BCYC
Q4 25
48.8%
-51.5%
Q3 25
48.3%
-558.6%
Q2 25
45.3%
-2965.8%
Q1 25
52.8%
-703.7%
Q4 24
52.2%
Q3 24
-59.1%
-2385.9%
Q2 24
1.3%
-498.3%
Q1 24
33.1%
-162.4%
Net Margin
BCAL
BCAL
BCYC
BCYC
Q4 25
35.8%
-42.0%
Q3 25
34.7%
-503.7%
Q2 25
31.8%
-2703.8%
Q1 25
37.6%
-608.9%
Q4 24
37.7%
Q3 24
-43.2%
-1898.4%
Q2 24
0.9%
-425.3%
Q1 24
22.5%
-136.0%
EPS (diluted)
BCAL
BCAL
BCYC
BCYC
Q4 25
$0.50
$-0.29
Q3 25
$0.48
$-0.85
Q2 25
$0.43
$-1.14
Q1 25
$0.52
$-0.88
Q4 24
$0.54
Q3 24
$-0.59
$-0.74
Q2 24
$0.01
$-0.77
Q1 24
$0.26
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCAL
BCAL
BCYC
BCYC
Cash + ST InvestmentsLiquidity on hand
$399.9M
$628.1M
Total DebtLower is stronger
$33.8M
Stockholders' EquityBook value
$576.6M
$610.0M
Total Assets
$4.0B
$717.6M
Debt / EquityLower = less leverage
0.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCAL
BCAL
BCYC
BCYC
Q4 25
$399.9M
$628.1M
Q3 25
$559.2M
$648.3M
Q2 25
$430.1M
$721.5M
Q1 25
$439.2M
$793.0M
Q4 24
$388.2M
$879.5M
Q3 24
$614.4M
$890.9M
Q2 24
$104.7M
$961.4M
Q1 24
$86.5M
$457.0M
Total Debt
BCAL
BCAL
BCYC
BCYC
Q4 25
$33.8M
Q3 25
$33.4M
Q2 25
$52.9M
Q1 25
$70.3M
Q4 24
$69.7M
Q3 24
$69.1M
Q2 24
$42.9M
$30.9M
Q1 24
$44.9M
$30.8M
Stockholders' Equity
BCAL
BCAL
BCYC
BCYC
Q4 25
$576.6M
$610.0M
Q3 25
$564.7M
$618.5M
Q2 25
$547.6M
$668.9M
Q1 25
$531.4M
$740.3M
Q4 24
$511.8M
$793.1M
Q3 24
$498.1M
$831.0M
Q2 24
$293.2M
$873.8M
Q1 24
$292.5M
$356.0M
Total Assets
BCAL
BCAL
BCYC
BCYC
Q4 25
$4.0B
$717.6M
Q3 25
$4.1B
$764.0M
Q2 25
$4.0B
$832.2M
Q1 25
$4.0B
$883.9M
Q4 24
$4.0B
$956.9M
Q3 24
$4.4B
$996.7M
Q2 24
$2.3B
$1.1B
Q1 24
$2.3B
$547.1M
Debt / Equity
BCAL
BCAL
BCYC
BCYC
Q4 25
0.06×
Q3 25
0.06×
Q2 25
0.10×
Q1 25
0.13×
Q4 24
0.14×
Q3 24
0.14×
Q2 24
0.15×
0.04×
Q1 24
0.15×
0.09×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCAL
BCAL
BCYC
BCYC
Operating Cash FlowLast quarter
$57.3M
$-19.3M
Free Cash FlowOCF − Capex
$56.9M
$-19.9M
FCF MarginFCF / Revenue
124.1%
-41.5%
Capex IntensityCapex / Revenue
0.8%
1.2%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$93.1M
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCAL
BCAL
BCYC
BCYC
Q4 25
$57.3M
$-19.3M
Q3 25
$16.0M
$-71.2M
Q2 25
$13.4M
$-72.8M
Q1 25
$7.0M
$-86.4M
Q4 24
$50.3M
$-164.7M
Q3 24
$18.3M
$-39.8M
Q2 24
$309.0K
$-44.6M
Q1 24
$8.1M
$-70.9M
Free Cash Flow
BCAL
BCAL
BCYC
BCYC
Q4 25
$56.9M
$-19.9M
Q3 25
$15.9M
$-71.8M
Q2 25
$13.4M
$-73.3M
Q1 25
$6.9M
$-87.0M
Q4 24
$49.7M
$-166.0M
Q3 24
$18.1M
$-40.3M
Q2 24
$171.0K
$-45.0M
Q1 24
$8.0M
$-70.9M
FCF Margin
BCAL
BCAL
BCYC
BCYC
Q4 25
124.1%
-41.5%
Q3 25
35.1%
-612.3%
Q2 25
30.2%
-2509.7%
Q1 25
15.3%
-871.7%
Q4 24
109.2%
-4475.7%
Q3 24
47.5%
-1504.7%
Q2 24
0.8%
-481.2%
Q1 24
36.4%
-362.9%
Capex Intensity
BCAL
BCAL
BCYC
BCYC
Q4 25
0.8%
1.2%
Q3 25
0.2%
5.7%
Q2 25
0.1%
17.1%
Q1 25
0.2%
6.1%
Q4 24
1.2%
33.3%
Q3 24
0.5%
16.3%
Q2 24
0.6%
4.5%
Q1 24
0.4%
0.1%
Cash Conversion
BCAL
BCAL
BCYC
BCYC
Q4 25
3.49×
Q3 25
1.02×
Q2 25
0.95×
Q1 25
0.41×
Q4 24
3.00×
Q3 24
Q2 24
1.63×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons